Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Associated Press

Scientists reported today that they have figured out how the popular illicit stimulant Captagon works and that they may have a way to combat its effects.

  • Captagon or fenethylline is popular in Saudi Arabia and throughout the Gulf (where counterfeit pills also abound).
  • There have been reports of the "Jihadi pill" being used by ISIS fighters as a performance stimulator—though that has been questioned.
  • The drug was first used in the 1960s to treat attention deficit hyperactivity disorder and narcolepsy but became illegal in most countries, including the U.S., in the 1980s after its addictiveness became apparent.

How it works: When ingested, fenethylline is broken down to the stimulant amphetamine and theophylline (a caffeine-like substance that relaxes the muscles around the lungs and is used to treat respiratory diseases). It was unclear how exactly the drug works in the body. Kim Janda and his colleagues from Scripps Research Institute found the combination of theophylline and amphetamine greatly enhances amphetamine's psychoactive properties.

"This drug is much more dangerous than was previously thought in terms of its overall psychoactive properties. We need greater awareness of the issues and its abuse effects" Janda said in a press conference.

What they did: The researchers made fenethylline in the lab (producing it is relatively easy and it's believed to be a revenue source for ISIS). They then vaccinated mice against the different components of fenethylline, administered the drug and determined how each substance affected their vigilance and movement, as well as the drug's uptake by the brain and body.

"The two drugs act synergistically and individually to hit their targets at the same time and it boosts the overall stimulant effect. What we see with the combination of these two drugs is we get a faster onset of the amphetamine properties and much stronger than what you would [normally] see — that was completely unexpected and unknown. It really explains why this drug is being so heavily abused," says Janda.

Janda, who is working on a vaccine for heroin, says the initial intent of the study wasn't a vaccine for fenethylline but that the study vaccine's components could be adjusted if there was interest in developing a vaccine for humans.

A term to know: Pharmacoterrorism refers to drugs originally produced for therapeutic benefit being abused in terror attacks for morale building or hypervigilance or to therapeutic drugs being weaponized.

Important side note: The researchers say their vaccine approach could be used to better understand how other drugs affect the brain. "[Natural products, anti-depressants, anti-psychotics, anti-seizure and other complex drugs] typically have multiple targets and figuring out how they interact with those targets is challenging. This approach can be used to figure out what effects are useful and helpful, and which are toxic or potentially link with abuse liabilities," says Janda.

Go deeper

Dion Rabouin, author of Markets
8 mins ago - Economy & Business

The fragile recovery

Data: Department of Labor; Chart: Axios Visuals

The number of people receiving unemployment benefits is falling but remains remarkably high three weeks before pandemic assistance programs are set to expire. More than 1 million people a week are still filing for initial jobless claims, including nearly 300,000 applying for pandemic assistance.

By the numbers: As of Nov. 14, 20.2 million Americans were receiving unemployment benefits of some kind, including more than 13.4 million on the Pandemic Unemployment Assistance (PUA) and Pandemic Emergency Unemployment Compensation (PEUC) programs that were created as part of the CARES Act and end on Dec. 26.

Ben Geman, author of Generate
28 mins ago - Politics & Policy

The top candidates Biden is considering for key energy and climate roles

Photo: Alex Wong/Getty Images

Senate Minority Leader Chuck Schumer (D-N.Y.) has urged President-elect Joe Biden to nominate Mary Nichols, chair of California's air pollution regulator, to lead the Environmental Protection Agency, Bloomberg reports.

Why it matters: The reported push by Schumer could boost Nichol's chances of leading an agency that will play a pivotal role in Biden's vow to enact aggressive new climate policies — especially because the plan is likely to rest heavily on executive actions.

U.S. economy adds 245,000 jobs in November as recovery slows

Data: BLS; Chart: Axios Visuals

The U.S. economy added 245,000 jobs in November, while the unemployment rate fell to 6.7% from 6.9%, the government said on Friday.

Why it matters: The labor market continues to recover even as coronavirus cases surge— though it's still millions of jobs short of the pre-pandemic level. The problem is that the rate of recovery is slowing significantly.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!